In experimental animal models of multiple sclerosis are rare in ONND (3%) and rheumatoid arthritis (10%). Anti-MBP IgG antibodies, however, are a frequent finding demyelinating antibody responses are directed against the in ONND (23%) and rheumatoid arthritis (60%). 
Introduction
The molecular and cellular mechanisms responsible for the scar tissue. The immunopathology of multiple sclerosis lesions is heterogeneous suggesting that lesion formation is selective destruction of CNS myelin in multiple sclerosis are unknown. Multiple sclerosis is believed to be an immune mediated by different effector mechanisms in discrete subsets of patients (Ozawa et al., 1994; Lucchinetti et al., mediated disease , in which a cascade of autoimmune events leads to the formation of persistently demyelinated gliotic 1996). In particular there is increasing evidence that antibody-dependent effector mechanisms can play an important role multiple sclerosis is associated with a persistent antibody response to MOG-Ig, whereas this response is only transient in the immunopathogenesis of demyelination.
Immunoglobulin (Ig) deposition within white matter lesions in OIND. Our results further suggest that antibodies to MOGIg arise early in the course of multiple sclerosis, whereas (Prineas, 1985) , Ig-associated receptor mediated phagocytosis of myelin debris by macrophages (Prineas and Graham, 1981;  antibodies to MBP accumulate over time. Prineas, 1985) and complement activation within the CNS (Gay and Esiri, 1991; Storch et al., 1998a) all provide indirect evidence for the involvement of antibody in disease
Methods
pathogenesis. This concept is further supported by the colocalization of IgG and C9neo, a marker for the final lytic
CSF and serum samples
Paired CSF and serum samples were obtained between 1993 stage of the complement cascade at the active leading edge of demyelinating lesions (Storch et al., 1998a) , and the and 1998 during diagnostic or therapeutic lumbar puncture from patients with given informed consent, and were stored presence of myelin debris coated with complement membrane attack complex in the CSF (Scolding et al., 1989) . However, at -20°C until use. All CSF samples were routinely analysed for mononuclear cell count, albumin-quotients (Q-Alb), CSF the antigen(s) recognized by this putative pathogenic autoantibody response remain to be identified.
oligoclonal bands and IgG-indices (Link and Tibbling, 1977; McLean et al., 1990) . The clinical and CSF data of all A promising target for this demyelinating antibody response is the myelin oligodendrocyte glycoprotein (MOG), patients analysed in this study are shown in Table 1 . Multiple sclerosis patients were diagnosed according to the criteria of which was initially identified as the dominant target for the demyelinating autoantibody response in experimental Poser and colleagues (Poser et al., 1983) and the degree of disability was scored using the expanded disability status autoimmune encephalomyelitis induced by immunization with CNS tissue homogenates (Lebar et al., 1986; Linington scale (EDSS; Kurtzke, 1983) . The multiple sclerosis cohort (130 patients, age range 13-72 years) included 50 patients and Lassmann, 1987) . MOG is a minor component of CNS myelin that is exclusively expressed at the outer surface of with relapsing-remitting disease course (multiple sclerosis-RR, age range 14-70 years) and 38 patients with chronic the myelin sheath and oligodendrocyte plasma membrane (Brunner et al., 1989) . A single Ig V-like domain (Gardinier progressive disease course (multiple sclerosis-CP, age range 16-72 years). We have also included 42 patients with their et al., 1992) exposed at the membrane surface (Kroepfl et al., 1996) provides the target for the demyelinating antibody first attack of multiple sclerosis (laboratory-supported definite multiple sclerosis; multiple sclerosis-R0, age range 13-59 response (Adelmann et al., 1995) . This Ig domain is unique in that it contains encephalitogenic T-cell epitopes which years), all of whom have later developed clinically definite multiple sclerosis. None of the multiple sclerosis patients synergize with this demyelinating antibody response to induce a demyelinating variant of experimental autoimmune analysed in this study had received either corticosteroids and/ or other immunosuppressive treatment in the 6 months prior encephalomyelitis in rats (Adelmann et al., 1995) , mice (Amor et al., 1994) and marmosets (Genain et al., 1995) .
to CSF and serum sampling. Thirty-two patients with OIND (age range 12-89 years) The pathology of these animal models closely resembles that seen in a subset of multiple sclerosis patients (Ozawa et al., and 30 patients with ONND (age range 12-80 years) served as controls. Patients with OIND included 16 1994; Lucchinetti et al., 1996; Storch et al., 1998a, b) .
Although enhanced T-and B-cell responses to MOG patients with viral neurological diseases (viral meningitis, 10 patients; meningoencephalitis, 4 patients; and encephalitis, have been reported in multiple sclerosis (Sun et al., 1991; Xiao et al., 1991; Kerlero de Rosbo et al., 1993; Wallström 2 patients) ; and 16 patients with bacterial neurological diseases (bacterial meningitis, 7 patients; and meningoet al., 1998 ) the role of these responses in disease pathogenesis is uncertain. In particular, no information is available with encephalitis, 9 patients). ONND patients included patients with headaches (13 patients); back pain (4 patients); cerebrorespect to either the frequency or titre of antibody responses directed against the extracellular MOG Ig domain (MOGvascular disease (3 patients); amyotrophic lateral sclerosis (2 patients); dementia (2 patients); psychosis (2 patients); Ig), which is the target of the pathogenic autoantibody response to this antigen.
cerebral neoplasm (1 patient); non-inflammatory neuropathy (1 patient); head trauma (1 patient) and Parkinson's disease In this retrospective study we used recombinant human MOG-Ig to determine the frequency and titres of MOG (1 patient). The clinical and CSF data of all controls analysed in this study are also shown in Table 1 . specific autoantibodies in multiple sclerosis patients. Moreover, we have also determined the frequency of autoantibodies Ten patients with rheumatoid arthritis served as a control for a chronic systemic inflammatory disease without CNS against another myelin antigen, myelin basic protein (MBP). We analysed paired serum and CSF samples from 130 involvement (Table 1) . Ten multiple sclerosis patients seropositive for anti-MOGmultiple sclerosis patients, 32 patients with other inflammatory neurological diseases (OIND), 30 patients with other Ig antibodies (3 multiple sclerosis-R0, 4 multiple sclerosis-RR and 3 multiple sclerosis-CP patients) have been reinvestigated non-inflammatory neurological diseases (ONND) and 10 patients with rheumatoid arthritis. We demonstrate that between 9 and 43 months (mean 21.2 Ϯ 10.6 months) after first analysis. At the time of this second investigation 7 MOG-Ig were pooled and applied at a Mono-SP-cationic exchange column (Pharmacia, Uppsala, Sweden) in ureapatients had multiple sclerosis-RR and 3 patients had multiple sclerosis-CP disease courses. Six anti-MOG-Ig seropositive buffer, pH 4.5. After washing with 100 mM NaCl in ureabuffer, pH 4.5, bound MOG-Ig fusion proteins were eluted OIND patients (2 patients with viral and 4 patients with bacterial inflammation) have also been reinvestigated between with a linear NaCl-gradient from 200 to 500 mM in ureabuffer, pH 4.5. Fractions containing MOG-Ig were pooled, 0.5 and 23 months (mean 8.6 Ϯ 9.2 months) after first analysis.
dialysed against 4 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris-HCl, pH 4.5, and stored at -20°C. As a control we have used recombinant mouse
Antigens and antibodies
A 102-amino acid long N-terminal MOG peptide (amino dihydrofolate reductase encoded by the control plasmid pQE-16 (Qiagen). Dihydrofolate reductase was produced and acids 28-130) including the MOG immunoglobulin superfamily domain (without the leader peptide sequence) was purified according to the manufacturer's instructions. MBP was purified from normal human brain according to expressed in the QuiaExpress Type III expression system (Qiagen, Hilden, Germany). The recombinant protein the procedure of Eylar and colleagues (Eylar et al., 1979) . Purity of the MOG-Ig and MBP preparations was confirmed contains six histidine residues fused to the C-terminus of MOG-Ig in order to allow affinity purification on a Niby SDS (sodium dodecyl sulphate)-PAGE (polyacrylamide gel electrophoresis) and Western blot analysis using the NTA agarose column (Qiagen). Briefly, the coding cDNA sequence (GenBank Accession X74511) was amplified following monoclonal antibodies: anti-MBP 130-137 (Boehringer-Mannheim, Mannheim, Germany) and antifrom a human brain cDNA by the polymerase chain reaction using primers introducing artificial PstI and BglII MOG 8.18-C5 (Linington et al., 1984) . restriction sites (5Ј-GGGCTGCAGGGCAGTTCAGAGTG-ATAG and 5Ј-GGGAGATCTCGGAAGAAGCAGGTGA-AAC). The 319 bp long amplified fragment was digested
Western blot analysis and ELISA
Western blot analysis was performed using standard with PstI and BglII and ligated with BglI/PstI digested PQE50 and BglI/BglII digested pQE17 plasmid vector methods. Briefly, either 1 µg recombinant MOG-Ig or 2 µg MBP was loaded per lane and separated in 14% SDSarms, thus creating a MOG-Ig expression plasmid. Ligated plasmids were then used for transformation of Escherichia polyacrylamide gels (Novex, San Diego, Calif., USA). Separated proteins were electrotransferred to nitrocellulose coli M15 host-cells. The identity of MOG-Ig expression plasmids was verified by sequence analysis. Expression membranes (Pharmacia). Efficiency of transfer was monitored by the use of a prestained low range SDS-PAGE standard and affinity purification of the recombinant protein was performed as recommended by the manufacturer Briefly, (Bio-Rad, Hercules, Calif., USA) and by staining of the filters with Ponceau S (Sigma, St Louis, Mo., USA) after recombinant MOG-Ig was affinity purified on Ni-NTA agarose columns (Qiagen) under denaturing conditions in transfer. Blots were blocked with 2% milk powder in PBS (phosphate-buffered saline) containing 0.05% Tween-20 urea-buffer (8 M urea, 100 mM NaH 2 PO 4 , 10 mM TrisHCl), pH 8.0. Bound fusion proteins were eluted by a (PBS-T). Blots were then dried, cut into 2 mm nitrocellulose strips using a membrane cutter (Novex) and probed with shift in pH from 8 to 4.5. Fractions containing recombinant diluted human sera (1 : 1000 in 2% milk powder in PBS-T) or CSFs (1 : 10 in 2% milk powder in PBS-T, or if necessary normalized for CSF IgG) overnight at 4°C. Approximately 10 µg of serum IgG and 5 µg of CSF IgG were used for Western blot analysis. Nitrocellulose strips were then washed three times with PBS-T and incubated with alkaline phosphatase conjugated anti-human IgG (JGH055003; Axell, Westbury, NY, USA) or anti-mouse IgG (JGM055003; Axell) for 1 h at room temperature. All antibodies were diluted 1 : 5000 in 2% milk powder in PBS-T. After washing, bound antibodies were detected by p-nitro-blue tetrazolium chloride (Boehringer-Mannheim) and 5-bromo-4-chloro-3-indolyl phosphate (Boehringer-Mannheim) in 100 mM Tris-HCl, 50 mM MgCl 2 , 100 mM NaCl pH 9.5.
ELISA was performed using 96-well Nunc-Immuno human IgG antibodies (see above), diluted in 0.5% BSA in PBS-T, were added and incubated for 1 h at room temperature. Reaction products were visualized with p-nitrophenylphosconfirmed by control experiments using the pre-absorption of sera with a similarly prepared recombinant control phate (Sigma) in 1 M diethanolamine, 5 mM MgCl 2 , pH 9.8, and the optical density determined at 405 nm. Control wells protein.
Since antibody responses to MBP also occur in multiple sclerosis patients (Paterson et al., 1981 ; Newcombe were coated with BSA and all data were corrected by subtraction of these background values. End-point titres Olsson et al., 1990; Warren and Catz, 1994; Sellebjerg et al., 1995) we used human myelin derived Western blot positive sera and CSFs were measured by ELISA using serial dilutions of sera (1 : 500 to 1 : 64 000 MBP for comparative studies. Seropositivity was initially determined by Western blotting (Fig. 1) ; the sensitivity of for IgG) and CSFs (1 : 5 to 1 : 640).
the assay was comparable for both responses (anti-MOG-Ig antibodies, 1 ng; anti-MBP antibodies, 0.8 ng). As shown in Table 2 , the frequency of anti-MOG-Ig
Statistical evaluation
antibody responses in multiple sclerosis patients was comStatistical analysis (means, standard deviations, medians) and parable with that seen in OIND. However, the frequency of significance of group differences (χ 2 and Mann-Whitney U patients seropositive for an anti-MBP antibody response was tests) were evaluated using the SPSS statistical analysis significantly lower in multiple sclerosis patients than in program (SPSS Inc., Chicago, Ill., USA). P values Ͻ 0.05 OIND. In contrast, almost all ONND were negative for were considered as statistically significant.
anti-MOG-Ig serum antibodies, but 23% of these patients Anti-MOG-Ig specific IgG-indices were calculated in a exhibited an anti-MBP antibody response. Therefore, in similar way to the total IgG-index (Link and Tibbling, 1977) multiple sclerosis the antibody response to these two myelin using the following formula: (CSF titre/serum titre)/(CSF antigens is dominated by the anti-MOG-Ig response, in OIND albumin/serum albumin).
the frequency of anti-MOG-Ig and anti-MBP responses is approximately equal, whereas in ONND the immune response is dominated by MBP.
Results
Finally we were interested in whether these antibody
Differential serum antibody responses to
responses observed in CNS inflammation are also present
MOG-Ig and MBP in multiple sclerosis patients
in chronic systemic inflammatory diseases without CNS involvement. Therefore we analysed serum samples from
and other neurological diseases
We screened the sera of 130 multiple sclerosis and 72 control patients with rheumatoid arthritis. Interestingly only one out of 10 of this control group was seropositive for anti-MOGpatients for IgG autoantibodies to recombinant human MOGIg by Western blot analysis. Specificity of our assay was Ig antibodies, whereas six patients were seropositive for anti- The number and percentage of positive sera reacting with recombinant human MOG-Ig and MBP purified from neurologically healthy human brain was determined by Western blot analysis (see Methods). Group differences were calculated using the χ 2 test; P values Ͻ 0.05 were considered as statistically significant. Values which are significantly different from each other are linked by a square bracket. n ϭ number of patients analysed. OIND, 1st analysis 6 0 6 (100%) 3 (50%) 3 (50%) OIND, 2nd analysis 6 9 (9) 0 (0%) 1 (17%) 0 (0%)
The number and percentage of positive sera reacting with recombinant human MOG-Ig and MBP purified from neurologically healthy human brain were determined by Western blot analysis (see Methods). n ϭ number of patients analysed; months ϭ time of second analysis in months. *Mean values with standard deviations given in parenthesis.
MBP antibodies (Table 2) indicating that in non-neurological Antibody responses in multiple sclerosis-R0 are therefore dominated by the anti-MOG-Ig response, whereas the inflammation anti-MBP antibodies are more common than antibodies to MOG-Ig.
incidence of anti-MBP antibodies increases with time.
We have then used a human MOG-Ig specific ELISA to determine end-point titres of anti-MOG-Ig Western blot positive sera. Both assays showed similar sensitivities (1 ng
The antibody response to MOG-Ig persists in of anti-MOG-Ig specific antibodies). Serum anti-MOG-Ig multiple sclerosis, but is transient in OIND
antibody titres ranged from 1 : 1000 to 1 : 32000 (Fig. 2) . Antibody responses to MOG-Ig and MBP were analysed in However, anti-MOG-Ig titres are comparable in all groups follow-up sera from anti-MOG-Ig seropositive patients with analysed indicating that titres do not increase with multiple multiple sclerosis and OIND by Western blot analysis. As sclerosis disease severity. shown in Table 3 the anti-MOG-Ig response persisted in the sera of all 10 multiple sclerosis patients available for this study, and an additional 30% of the patients became seropositive for MBP. In contrast, the anti-MOG-Ig antibody
Intrathecal synthesis of anti-MOG-Ig
response was no longer detectable in OIND sera after a mean autoantibodies interval of 9 months.
In view of the reported compartmentalization of anti-myelin antibody responses in the CNS of multiple sclerosis patients (Moller et al., 1989; Olsson et al., 1990; Baig et al., 1991b;  Frequencies of serum antibodies to MOG-Ig Sun et al., 1991; Xiao et al., 1991; Warren and Catz, 1994;  and MBP in different multiple sclerosis Sellebjerg et al., 1995) we analysed the CSFs obtained from patients with multiple sclerosis, OIND and ONND for the
subgroups
The antibody response to MOG-Ig was subsequently analysed presence of MOG-Ig specific IgG antibodies by Western blotting (Table 5) . Titres of anti-MOG-Ig antibody positive in patients stratified for the defined subsets of multiple sclerosis (Table 4) . Whereas the frequency of anti-MOG-Ig patients were subsequently determined by ELISA (Fig. 2) . In general, the frequency of the anti-MOG-Ig response in antibody positive patients is similar in multiple sclerosis-R0, multiple sclerosis-RR and multiple sclerosis-CP, there are multiple sclerosis and OIND was similar in CSF and serum suggesting that the CSF antibody response to MOG-Ig is clear differences between these multiple sclerosis subgroups regarding the anti-MBP antibody response. Anti-MBP antirelated to that seen in the patients' sera. The highest frequency of CSF anti-MOG-Ig antibodies was seen in OIND, whereas body responses are low in early multiple sclerosis and increase significantly with disease duration and conversion ONND CSF was uniformly negative for anti-MOG-Ig antibodies. In order to determine whether in multiple sclerosis to either multiple sclerosis-RR or multiple sclerosis-CP. The number and percentage of positive sera reacting with recombinant human MOG-Ig and MBP purified from neurologically healthy human brain was determined by Western blot analysis (see Methods). Group differences were calculated using the χ 2 test; P values Ͻ 0.05 were considered as statistically significant. Values which are significantly different from each other are linked by a square bracket. n ϭ number of patients analysed. are associated with pathological CSF mononuclear cell numbers and Q-Albs indicating extensive blood-brain barrier damage and leakage from the peripheral blood. In contrast, the CSF anti-MOG-Ig positive multiple sclerosis patients had Neuropathological findings suggest that antibodies play an important role in lesion formation in a subset of multiple sclerosis patients (Prineas and Graham, 1981; Prineas, 1985 ; the synthesis of anti-MOG-Ig antibodies is to any extent compartmentalized within the CNS, we compared MOG-Ig Gay and Esiri, 1991; Ozawa et al., 1994; Lucchinetti et al., 1996; Storch et al., 1998a) , but their target specificity is specific IgG-indices, total IgG-indices, CSF cell counts and Q-Albs for CSF anti-MOG-Ig IgG positive and negative unknown. Autoantibodies recognizing several myelin proteins including MBP (Paterson et al., 1981; Newcombe et al., patients (Table 6 ). MOG-Ig specific and total IgG-indices were significantly higher in CSF anti-MOG-Ig positive 1985; Olsson et al., 1990; Warren and Catz, 1994; Sellebjerg et al., 1995) , proteolipid protein (Warren and Catz, 1994; multiple sclerosis patients than in their CSF anti-MOG-Ig positive OIND counterparts, whereas Q-Albs and CSF cell Sellebjerg et al., 1995) , myelin-associated glycoprotein (Moller et al., 1989; Baig et al., 1991b) and 2Ј,3Ј-cyclic counts were significantly higher in OIND. CSF anti-MOGIg IgG antibodies in multiple sclerosis are therefore strongly nucleotide 3Ј-phosphodiesterase (Walsh and Murray, 1998) are present in multiple sclerosis patients, but their role in associated with high anti-MOG-Ig specific and total IgGindices indicating intrathecal anti-MOG-Ig antibody disease pathogenesis is enigmatic and controversial. Animal models and in vitro studies failed to demonstrate a pathogenic synthesis, whereas in OIND CSF anti-MOG-Ig antibodies 0.6 (0.1) -
The numbers and percentage of positive CSFs reacting with recombinant human MOG-Ig were determined by Western blot analysis, and total IgG-indices and specific anti-MOG-Ig IgG-indices were calculated (see Methods). Group differences were calculated using the Mann-Whitney U test; P values Ͻ 0.05 were considered as statistically significant. Values which are significantly different from each other are linked by a square bracket. n ϭ number of patients analysed. *Mean values with standard deviations given in parenthesis.
role for autoantibody responses against any of these multiple sclerosis and OIND, anti-MBP antibodies were also found in patients with non-inflammatory CNS diseases. myelin proteins. Antisera raised against MBP (Mithen et al., 1982a, b) , proteolipid protein (Mithen et al., 1980; Seil and Moreover, the anti-MOG-Ig antibody response appears to be established early in the course of multiple sclerosis and does Agrawal, 1980) or myelin-associated glycoprotein (Seil et al., 1981) are unable to mediate demyelination either in vivo or not then differ significantly between the different patient subsets. In contrast, the anti-MBP response appears to in myelinating organotypic CNS cultures in vitro. In contrast MOG specific autoantibodies mediate demyelination in vitro accumulate with time. Our finding of enhanced anti-MBP antibody responses in advanced multiple sclerosis, OIND, (Kerlero de Rosbo et al., 1990) and in vivo (Schluesener et al., 1987; Linington et al., 1988) . In rodent and primate ONND and rheumatoid arthritis is comparable with previous reports (Frick and Stickl, 1980; Paterson et al., 1981 ; models of experimental autoimmune encephalomyelitis, MOG is the immunodominant target for this demyelinating Newcombe et al., 1985; Baig et al., 1991a; Solders et al., 1992; Wang et al., 1992; Olsson et al., 1993) indicating that autoantibody response, which is directed against the extracellular Ig domain of the protein (Adelmann et al., an anti-MBP antibody response is a relatively common sequel to any CNS injury. Moreover, even in our small number of 1995; Genain et al., 1995) . However, although the pathogenic role of the anti-MOG antibody response is well established patients with chronic systemic inflammatory disease we could demonstrate a common antibody response to MBP but not in animal models, there is as yet no evidence that this is also the case in multiple sclerosis.
MOG-Ig. However, although our data indicate that anti-MOG-Ig antibodies tend to be more associated with CNS MOG specific autoantibody and B-cell responses have been reported in multiple sclerosis, but their epitope specificity, in inflammation than anti-MBP antibodies, further studies are needed to confirm this particular observation. particular whether or not they recognized the pathogenic Ig domain, was not described (Sun et al., 1991; Xiao et al., 1991) .
The differential humoral responses to MOG-Ig and MBP observed in this study may reflect differences in antigen However, a recent study has demonstrated the association of MOG specific autoantibodies with myelin debris in multiple concentration, sequestration by the blood-brain barrier and immunogenicity. MBP accounts for approximately 30% of sclerosis lesions, indicating that they may well be involved in lesion formation (Genain et al., 1999) . In the present study the CNS myelin membrane protein, whereas MOG is a minor component of the myelin sheath (0.01-0.05% of the total we demonstrate that a substantial subset of multiple sclerosis patients mount a sustained autoantibody response to the membrane protein; Brunner et al., 1989) . In addition, MBP is not a CNS myelin specific protein; it is also expressed in extracellular Ig domain of MOG that may be directly involved in disease pathogenesis. the peripheral nervous system and cells of the immune system (Pribyl et al., 1996) . In contrast, MOG is exclusively This MOG-Ig specific antibody response is, however, not a specific feature of multiple sclerosis, as similar frequencies expressed in oligodendrocytes (Gardinier et al., 1992) and is therefore sequestered from the immune system by the and titres are present in the sera and CSFs of patients with acute CNS inflammation. Acute viral or bacterial CNS endothelial blood-brain barrier and lack of direct lymphoid drainage from the CNS compartment. However, it is apparent diseases are monophasic, which correlates with the observed transient autoantibody response to both MOG-Ig and MBP.
that immune sequestration does not render MOG uniformly immunogenic in all patients, as only 40-50% of multiple In contrast, multiple sclerosis was characterized by a persistent anti-MOG-Ig antibody response suggesting that a sclerosis and OIND samples were anti-MOG-Ig antibody positive. chronic inflammatory response is necessary to sustain this autoantibody response.
The association of a sustained anti-MOG-Ig antibody response with multiple sclerosis is intriguing, but the Intriguingly, the characteristics of the antibody response to MOG-Ig differed dramatically from the response to MBP. demyelinating potential of this response has still to be proven. Moreover, the pathogenic potential of anti-MOG antibodies Unlike the anti-MOG-Ig response that was associated with both T-cell (Kerlero de Rosbo et al., 1993; Wallström et al., 33: 73-79. 1998) and antibody responses to MOG in multiple sclerosis patients suggests that a similar pathomechanism may be pathologically defined subset of multiple sclerosis patients (Prineas and Graham, 1981; Prineas, 1985 Kerlero de Rosbo N, Honegger P, Lassmann H, Matthieu JM.
